Lupin receives EIR from USFDA for Nagpur injectable facility

17 Dec 2025 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its injectable facility in Nagpur, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from September 8 to September 16, 2025.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2109.50 19.85 (0.95%)
17-Dec-2025 15:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.65
Dr. Reddys Lab 1271.90
Cipla 1495.10
Zydus Lifesciences 918.00
Lupin 2109.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×